Conference Coverage
Evobrutinib demonstrates efficacy, safety in relapsing MS
PHILADELPHIA – Primary endpoint of reducing enhancing lesions versus placebo was met with evobrutinib.
Conference Coverage
Fingolimod reduced disease activity more than glatiramer acetate in RRMS: ASSESS study results
PHILADELPHIA – Relapse rate and radiographic endpoints significantly improved with the 0.5-mg daily dose of fingolimod, with safety as expected...
Conference Coverage
Sugary drink intake may be associated with MS severity
PHILADELPHIA – Among patients with multiple sclerosis, consumption of sugar-sweetened beverages may be associated with more severe disability,...
News
BTK inhibitor reduces MS enhancing lesions
However, neither the 75-mg nor 25-mg dosing regimens significantly reduced Expanded Disability Status Scale scores, compared with placebo.
Conference Coverage
Changes in brain networks may predict MS worsening
PHILADELPHIA – Structural and functional network MRI measures appear to identify patients at high risk for increased...
Conference Coverage
Ibudilast’s efficacy differs in primary and secondary progressive MS
PHILADELPHIA – Efficacy in a phase 2 trial was driven by patients with primary progressive MS, which may be related to faster brain atrophy rates...
Conference Coverage
The art of selecting an MS therapy
DALLAS – Clinical and imaging findings may indicate disease phase, severity, and prognosis, which can inform the treatment choice.
Conference Coverage
Researchers examine vitamin D, skin pigmentation, and outcomes of pediatric MS
PHILADELPHIA – The association between vitamin D insufficiency and MS outcome in children appears to relate partly...
News
Criterion based on the central vein sign distinguishes between MS and mimics
PHILADELPHIA – Applying the criterion of three lesions with the central vein sign is feasible in clinical practice...
Conference Coverage
Eculizumab cuts relapse risk in NMO spectrum disorder
PHILADELPHIA – Nearly 98% of patients with this autoimmune inflammatory CNS disorder were relapse-free at 48 weeks in the randomized phase 3...
Conference Coverage
Multiple sclerosis may not flare up after pregnancy
PHILADELPHIA – Exclusive breastfeeding significantly reduced the risk of postpartum relapses.
Conference Coverage
A blood biomarker for MS: Coming to clinics soon?
DALLAS – Neurologists have lacked ways to monitor subclinical MS, but new developments suggest that blood levels of neurofilament light chain (NfL...
Conference Coverage
Cerebellar volume may predict disability in patients with relapsing-remitting MS
DALLAS – Baseline cerebellar gray matter volume was the only MRI metric that significantly predicted 25-foot walk test results at 36 months.
News
FDA approves Mavenclad for treatment of relapsing MS
Cladribine (Mavenclad) is the first short-course oral therapy for adult patients with relapsing/remitting or active secondary progressive MS.
Conference Coverage
Imaging mass cytometry sheds light on inflammation, demyelination in MS
DALLAS – The technology enables clinicians to examine multiple proteins within intact tissue and distinguish cell types based on complex...
Conference Coverage
MS researchers aim to build MRI diagnostic portfolio beyond the central vein sign
DALLAS – Evaluation of lesion morphology is one emerging technology, according to Dr. Andrew J. Solomon.
Conference Coverage
Study launched to further evaluate the central vein sign in MS
DALLAS – A total of 10 clinical sites in North America are participating, with the Cleveland Clinic coordinating.
Conference Coverage
-
-
Fingolimod reduced disease activity more than glatiramer acetate in RRMS: ASSESS study results -
-
Changes in brain networks may predict MS worsening -
Ibudilast’s efficacy differs in primary and secondary progressive MS
Multimedia
Question 1 of 5